VANCOUVER, May 30, 2018 – Segra International Corp. (“Segra”) is pleased to announce that it has finalized an agreement with Agripharm Corp. (“Agripharm”) to incorporate Segra’s cannabis tissue culture micropropagation technology into Agripharm’s cannabis production systems, enabling Agripharm to rapidly scale up its production of disease-free, genetically verified cannabis plants.
“Segra is thrilled to assist Agripharm in scaling up production while maintaining the highest possible quality standards,” said Segra’s CEO and co-founder, Todd McMurray. “This is another huge milestone for Segra toward our goal of becoming the premier global brand in cannabis micropropagation.”
Working with Agripharm’s team, Segra will construct a tissue culture lab at the Agripharm facility in Creemore, Ontario in order to prepare numerous cultivars for the micropropagation process. Subject to performance milestones, production will then move to Segra’s dedicated cannabis micropropagation facility for mass production once construction and licensing are complete.
“Segra’s cannabis tissue culture technology will be an essential component of our cultivation process,” said Green House Seed Co. founder, Arjan Roskam. “As we tap into Green House Seed Co.’s award-winning genetics library, our number one priority will be ensuring that we can reliably reproduce the strains that consumers have come to love. We believe that using micropropagation will be a big leap forward in ensuring we can continue to deliver genetically accurate and disease-free products to market.”
“The benefits of integrating micropropagation into industrial-scale agricultural businesses are well documented; we expect this partnership to drive meaningful cost improvements while also improving product quality and increasing production efficiencies,” said Agripharm CEO and co-founder, Peter Miller. “This was a no-brainer.”
Agripharm Corp. is an ACMPR-licensed, 20,000 sq. ft. indoor growing facility based in Creemore, Ontario. The company is operated through a joint venture between Canopy Growth, Green House Holdings North America Inc. (Strainhunters, Green House Seed Co., King of Cannabis, and GH Medical), and Organa Brands (O.penVape, Magic Buzz, Bakked, and District Edibles).
Segra is an agricultural life sciences company specializing in cannabis plant micropropagation. The company is developing industrial-scale cannabis micropropagation laboratories in Canada and California to produce disease-free, genetically verified plantlets for licensed producers globally. Segra has assembled a world-class team of specialists in the areas of Plant Tissue Culture, agronomy, molecular genetics, regulatory compliance, and corporate finance. The Segra team includes Dr. Sma Zobayed, a world-renowned plant micropropagation specialist who has successfully micropropagated over 500 unique plant cultivars, including cannabis.
On behalf of the Board of Directors,
Todd McMurray, President/CEO
SEGRA INTERNATIONAL CORP.
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
For further information, contact